Oncorus Inc

NASDAQ:ONCR   3:59:40 PM EDT
25.10
-0.67 (-2.60%)
Other Pre-Announcement

Oncorus Reports Third Quarter 2020 Financial Results And Provides Business Highlights

Published: 11/11/2020 12:30 GMT
(ONCR) - Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights.
Q3 Loss per Share $21.73.
Expects to Have Sufficient Capital to Fund Its Operating Expenses and Capital Expenditure Requirements Into 2023.
Cash & Cash Equivalents Were $54.0 Million As of Sept 30, 2020, Excluding Proceeds From Co's Ipo in October 2020.
Plans to Nominate Its Oncr-gbm Clinical Candidate in Second Half of 2021.
Expects to Nominate Clinical Candidates for Both Lead Synthetic, Iv Administered Viral Immunotherapy Programs in H1 of 2021.